- Home
- ZION vs KYMR Comparison
ZION vs KYMR Comparison
Compare ZION & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | KYMR |
|---|---|---|
| Founded | 1873 | 2015 |
| Country | United States | United States |
| Employees | N/A | 273 |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.7B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZION | KYMR |
|---|---|---|
| Price | $63.25 | $105.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 24 |
| Target Price | $72.73 | ★ $139.35 |
| AVG Volume (30 Days) | ★ 1.4M | 782.2K |
| Earning Date | 10-19-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 21.41 | N/A |
| EPS | ★ 4.61 | N/A |
| Revenue | ★ $662,000,000.00 | $39,211,000.00 |
| Revenue This Year | $5.90 | $167.19 |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | $13.67 | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $48.50 | $55.26 |
| 52 Week High | $73.34 | $130.05 |
Technical Indicators
Market Signals| Indicator | ZION | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 39.59 |
| Support Level | $60.80 | $100.63 |
| Resistance Level | $63.94 | $119.89 |
| Average True Range (ATR) | 1.16 | 5.27 |
| MACD | 0.22 | -0.32 |
| Stochastic Oscillator | 64.60 | 26.95 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.